Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome

Cancer Chemother Pharmacol. 2008 Jun;62(1):181-2. doi: 10.1007/s00280-007-0574-9. Epub 2007 Aug 31.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents, Hormonal / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Boronic Acids / administration & dosage
  • Bortezomib
  • Dexamethasone / administration & dosage
  • Female
  • Humans
  • L-Lactate Dehydrogenase / blood
  • Middle Aged
  • Multiple Myeloma / complications
  • Multiple Myeloma / drug therapy*
  • Pyrazines / administration & dosage
  • Thalidomide / administration & dosage
  • Tumor Lysis Syndrome / complications*

Substances

  • Antineoplastic Agents
  • Antineoplastic Agents, Hormonal
  • Boronic Acids
  • Pyrazines
  • Thalidomide
  • Bortezomib
  • Dexamethasone
  • L-Lactate Dehydrogenase